Projects per year
Fingerprint
Dive into the research topics where Matthias D'Huyvetter is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
FWOIRI10: Research on radioactive nuclei at ISOLDE-CERN, SPIRAL2- GANIL and MEDICIS-CERN
Caveliers, V. & D'Huyvetter, M.
1/01/23 → 31/12/26
Project: Fundamental
-
HERC59: CASA PETIt: CAmera for Small Animal PET-Imaging
Devoogdt, N., Raes, G., Lahoutte, T., Van Ginderachter, J., Caveliers, V., Keyaerts, M., Hernot, S. & D'Huyvetter, M.
1/05/22 → 30/04/26
Project: Fundamental
-
FWOSB80: Combining targeted radionuclide therapy and cancer immunotherapy to advance precision medicine through innovation.
Breckpot, K., Devoogdt, N., D'Huyvetter, M., Keyaerts, M. & Ertveldt, T.
1/11/19 → 31/10/23
Project: Fundamental
-
FWOUW24: Visiting Polish researcher prof. Marek Pruszynski (22 - 28 september 2019)
22/09/19 → 28/09/19
Project: Fundamental
Research output
-
Efficient α and β- radionuclide therapy targeting fibroblast activation protein-α in an aggressive preclinical mouse tumour model
Ceuppens, H., Pombo Antunes, A. R., Navarro, L., Ertveldt, T., Berdal, M., Nagachinta, S., De Ridder, K., Lahoutte, T., Keyaerts, M., Devoogdt, N., Goyvaerts, C., D'Huyvetter, M. & Breckpot, K., 6 Sep 2024, (E-pub ahead of print) In: European Journal of Nuclear Medicine and Molecular Imaging.Research output: Contribution to journal › Article › peer-review
-
Generic semi-automated radiofluorination strategy for single domain antibodies: [18F]FB-labelled single domain antibodies for PET imaging of fibroblast activation protein-α or folate receptor-α overexpression in cancer
Dierick, H., Navarro, L., Ceuppens, H., Ertveldt, T., Pombo Antunes, A. R., Keyaerts, M., Devoogdt, N., Breckpot, K., D'Huyvetter, M., Lahoutte, T., Caveliers, V. & Bridoux, J., Dec 2024, In: EJNMMI Radiopharmacy and Chemistry. 9, 1, 14 p., 54.Research output: Contribution to journal › Article › peer-review
Open Access -
Optimised solid-phase extraction of 211At:Activity balance of 211At, 210At and 210Po after wet chemistry target dissolution
Sevenois, M. B., Jensen, H. J., Haddad, F., Bäck, T., D'Huyvetter, M., Navarro, L. & Covens, P., Dec 2024, In: Radiation Physics and Chemistry. 225, 7 p., 112146.Research output: Contribution to journal › Article › peer-review
Open Access -
Accepted poster session at ImmunoRad 2023: Targeted alpha therapy using Actinium-225 radiolabeled single domain antibodies induces antigen-specific immune responses and instills immunomodulation both systemically and at the tumor microenvironment
Ertveldt, T., Krasniqi, A., Ceuppens, H., Puttemans, J., Dekempeneer, Y., De Jonghe, K., de Mey, W., Lecocq, Q., De Vlaeminck, Y., Awad, R. M., Goyvaerts, C., De Veirman, K., Morgenstern, A., Bruchertseifer, F., Keyaerts, M., Devoogdt, N., D'Huyvetter, M. & Breckpot, K., 27 Sep 2023.Research output: Unpublished contribution to conference › Poster
-
A realistic multiregion mouse kidney dosimetry model to support the preclinical evaluation of potential nephrotoxicity of radiopharmaceutical therapy
Vargas, C. S., Struelens, L., D'Huyvetter, M., Caveliers, V. & Covens, P., 1 Mar 2023, In: Journal of Nuclear Medicine. 64, 3, p. 493-499 7 p., 264453.Research output: Contribution to journal › Article › peer-review
Open Access8 Citations (Scopus)
Prizes
-
Alavi-Mandell Award from Journal of Nuclear Medicine
Krasniqi, A. (Recipient), D'Huyvetter, Matthias (Recipient), Devoogdt, Nick (Recipient) & Keyaerts, Marleen (Recipient), 16 Apr 2019
Prize: Prize (including medals and awards)
-
Award of the Fonds Germaine Eisendrath Dubois (FGED)
D'Huyvetter, Matthias (Recipient), 2012
Prize: Prize (including medals and awards)
-
-
-
Travel Award of Fonds Wetenschappelijk Onderzoek - Vlaanderen (FWO)
D'Huyvetter, Matthias (Recipient), 7 Sep 2016
Prize: Prize (including medals and awards)
Activities
-
Astatine-211: 'The rarest material on earth is more accessible than you think'.
Matthijs Sevenois (Speaker), Laurent Navarro (Contributor), Matthias D'Huyvetter (Contributor) & Peter Covens (Contributor)
26 Apr 2024Activity: Talk or presentation › Talk or presentation at a conference
-
SCK NMA-talk
Thomas Ertveldt (Presenter), Nick Devoogdt (Invited speaker) & Matthias D'Huyvetter (Contributor)
14 Nov 2023Activity: Talk or presentation › Talk or presentation at a workshop/seminar
-
Optimization production yield of 211At
Matthijs Sevenois (Invited speaker), Matthias D'Huyvetter (Contributor), Ferid Haddad (Contributor) & Peter Covens (Contributor)
10 May 2023Activity: Talk or presentation › Talk or presentation at a workshop/seminar
-
Optimizing the yield of 211At
Matthijs Sevenois (Speaker), Holger Jensen (Contributor), Matthias D'Huyvetter (Contributor) & Peter Covens (Contributor)
16 Oct 2022Activity: Talk or presentation › Talk or presentation at a conference
-
A multi-region model of a mouse kidney for preclinical internal dosimetry of beta- and alpha-particle emitting radionuclides
Clarita Saldarriaga Vargas (Speaker), Lara Struelens (Contributor), Matthias D'Huyvetter (Contributor), Vicky Caveliers (Contributor) & Peter Covens (Contributor)
18 Oct 2022Activity: Talk or presentation › Talk or presentation at a conference
Press/Media
-
Brussels, City of Innovators - Matthias D'Huyvetter
28/01/21
1 Media contribution
Press/Media: Research
-
Camel blood to fight cancer? This VUB spin-off is getting amazing results
Tony Lahoutte, Nick Devoogdt, Matthias D'Huyvetter, Jens De Vos & Claudia Mebis
17/11/17
1 Media contribution
Press/Media: Research
-
Kanker bestrijden met elektrische fietsjes in het bloed
Tony Lahoutte, Ruth Devenyns, Nick Devoogdt, Matthias D'Huyvetter, Jens De Vos & Claudia Mebis
17/10/17
1 Media contribution
Press/Media: Research
-
Lama-antistoffen in strijd tegen kanker
Tony Lahoutte, Nick Devoogdt, Matthias D'Huyvetter, Jens De Vos & Claudia Mebis
30/03/17
1 Media contribution
Press/Media: Research
-
Wat is borstkanker en hoe wordt deze ziekte behandeld?
27/02/17
1 Media contribution
Press/Media: Research
Thesis
-
CD20 Nb TRNT: targeted radionuclide therapy of non-hodgkin-lymphoma with anti-CD20 nanobodies
Author: Devoogdt, N., D'Huyvetter, M. & Tavernier, J., 24 May 2019Student thesis: Doctoral Thesis
-
EGFRvIII Nb TRNT: Evaluation of radiolabeled nanobodies for the treatment of cancers expressing mutant EGFR’
Author: Puttemans, J., Devoogdt, N., D'Huyvetter, M. & Muyldermans, S., 4 Mar 2021Student thesis: Doctoral Thesis
-
Evaluation of anti-idiotype Nanobodies in a preclinical model of Multiple Myeloma
Author: Sharma, P., Puttemans, J., Devoogdt, N., D'Huyvetter, M. & Muyldermans, S., 2019Student thesis: Master's Thesis
-
Evaluation of TRNT-mediated immunogenic effects
Author: Krasniqi, A., Hugé, H. L. S., D'Huyvetter, M. & Raes, G., 2020Supervisor: Krasniqi, A. (Advisor)
Student thesis: Master's Thesis
-
Immunogenic effect of targeted radionuclide therapy-induced tumor cell death
Author: Ertveldt, T., Breckpot, K., Keyaerts, M., D'Huyvetter, M. & Krasniqi, A., 15 Jun 2019Supervisor: Krasniqi, A. (Promotor)
Student thesis: Master's Thesis